Alice Bendix Gottlieb
Southwestern Medical Center · 905 works · 51,140 citations · h-index 114
Top works
- Etanercept as Monotherapy in Patients with Psoriasis
- Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes.
- Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- Ia-bearing T lymphocytes in man. Their identification and role in the generation of allogeneic helper activity.
- Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial
- A Randomized Trial of Etanercept as Monotherapy for Psoriasis
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
- Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
- Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques.
- Two considerations for patients with psoriasis and their clinicians:
- Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
- Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques.
- Detection of transforming growth factor alpha in normal, malignant, and hyperproliferative human keratinocytes.
- A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis
- A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial